Navigation Links
Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
Date:9/30/2010

.54 per basic share, in fiscal year 2009. Non-GAAP adjusted diluted earnings per share were $2.04 in fiscal year 2010, as compared to $2.46 in fiscal year 2009.

Financial Condition

As of June 30, 2010, the Company had $108.6 million in cash, as compared to $104.4 million at the end of fiscal year 2009. Working capital was $88.5 million, down from $99.8 million as of June 30, 2009. Shareholders' equity was $134.5 million, as compared to $126.1 million at the end of fiscal year 2009.

The Company generated $20.3 million in cash flow from operating activities in fiscal year 2010. Net cash flow used in investing activities was $16.6 million in fiscal year 2010, which was primarily used to purchase land use rights of approximately $17.0 million, partially offset by proceeds of approximately $0.5 million from the sale of investments.

Due to restrictions on the Company's ability to transfer cash out of the PRC, the Company is delinquent in the payment of interest on its November 2007 Debentures and May 2008 Notes. Management has been in close discussions with holders of the November 2007 Debentures and May 2008 Notes in order to reach a resolution to this issue in the near-term.

Business Outlook and Guidance

Combined sales of the Company's top four products in fiscal year 2010 are expected to decline by 15% to 20% in fiscal year 2011, reflecting intensifying competition and the Chinese government's control over drug pricing under recent health care reform policies.

Incremental sales from the Company's recently approved Felodipine sustained release tablets and from the Company's TCM products to be manufactured at Hongrui are expected to largely offset this decline in 2011.

Management estimates that the portfolio of TCM drugs to be manufactured at Hongrui will generate revenues of $7 million to $15 million during the first year of production, beginning i
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
2. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
3. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
4. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
5. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
6. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Memorial Hermann Health System and The ... a new partnership to provide a new level of specialized ... in the greater Houston area. ... exclusive provider of professional breast radiology services for five of ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... ANGELES , Aug. 21, 2014 The spinal ... of the human body. Signals carried to and from the ... motor skills and nervous system. Injury or ailment here can ... or with a loss of control over their body. Though ... on a person,s life, there are more options available to ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 2011 Reportlinker.com announces that a new market ... Hospital MRI (Magnetic Resonance Imaging/Tomography) Census ... This is the most comprehensive European market report ... (General Radiology, Mammography, R&F, Angiography, CT, MRI,) and ...
... PITTSBURGH, Jan. 20, 2011 Mylan Inc. (Nasdaq: ... Laboratories Limited has received tentative approval from the U.S. ... Plan for AIDS Relief (PEPFAR) for its New Drug ... mg. The NDA is based on the reference listed ...
Cached Medicine Technology:Reportlinker Adds Hospital MRI (Magnetic Resonance Imaging/Tomography) Census 2Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Legal ... system created by Greg Marks has been generating a ... this month. The commotion surrounding the new product has ... investigative review. , “In recent years the ... software systems, commonly referred to as robots or ‘bots,'” ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final ... of ProIntro Vol.3, a customizable title tool for FCPX ... just by dragging ProIntro Vol.3 in their timeline" says Christina ... definite time saver and i think our users will agree" ... designed titles made with Final Cut Pro X users in ...
(Date:8/23/2014)... Teen substance abuse ranks as one of ... NC. Countless adolescents throughout North Carolina struggle with a drug ... never receive professional rehab due to a lack of information ... help. Troubled Teens Holly Springs is a helpline designed to ... teenage alcohol abusers in Wake County who are seeking ...
(Date:8/22/2014)... 2014 On Friday, Aug. 22, Liberty ... Health Sciences , hosting a ceremony in its courtyard ... government and public welfare. , The 162-member inaugural class ... (LUCOM) joined Liberty staff, faculty, and community leaders ... the new medical school. Classes began on Monday, Aug. ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... A-I ratio is not a better predictor of coronary ... total cholesterol and HDL-C, according to a study in ... instruments and guidelines for coronary heart disease (CHD) prevention ... cholesterol, or both for CHD risk assessment. But in ...
... scale, multiethnic study of its kind, researchers at UCLA ... known as cytokines as a cause of Type 2 ... biological markers that may be used to more accurately ... , Reporting in the August 15 issue of the ...
... improve their understanding of the potential increased risk of ... study conducted by researchers from The Childrens Hospital in ... New Haven, CT. , Like many radiology departments around ... exposure to children caused by increased usage of CT. ...
... Columbia University Medical Center researchers have demonstrated using ... was increased in stroke and traumatic brain injury ... rehabilitative treatment that helps these patients recover lost ... the peer-reviewed journal Neurorehabilitation and Neural Repair on ...
Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expan...
... antiplatelet drugs (e.g., acetylsalicylic acid) are key therapeutic ... this study, Joseph Delaney MSc, Dr. James Brophy ... cases with a diagnosis of gastrointestinal bleeding and ... documented a 46-fold increase in the rate of ...
Cached Medicine News:Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 3Health News:Informational handout key to giving parents a better understanding of CT radiation risks 2Health News:Vision restoration therapy shown to improve brain activity in brain injured patients 2
Take Performance to a Higher Level....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Galaxy IVUS Imaging System simplifies the process of intracardiac echo while delivering accurate, real-time diagnostic information in less time with less work. (Ultra ICE catheter compatible)...
Medicine Products: